How does antifungal pharmacology differ for mucormycosis versus aspergillosis?
about
Biology, systematics, and clinical manifestations of Zygomycota infectionsStability in the cumulative incidence, severity and mortality of 101 cases of invasive mucormycosis in high-risk patients from 1995 to 2011: a comparison of eras immediately before and after the availability of voriconazole and echinocandin-amphoterSudden death in a patient with bone marrow transplant by a fungus among usIn vitro combination of isavuconazole with micafungin or amphotericin B deoxycholate against medically important molds.Mitochondrial respiratory pathways inhibition in Rhizopus oryzae potentiates activity of posaconazole and itraconazole via apoptosis.Impact of Mucorales and Other Invasive Molds on Clinical Outcomes of Polymicrobial Traumatic Wound Infections.Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration.Tacrolimus enhances the potency of posaconazole against Rhizopus oryzae in vitro and in an experimental model of mucormycosisSafety, Tolerability, and Pharmacokinetics of Liposomal Amphotericin B in Immunocompromised Pediatric Patients.Epidemiology and treatment of mucormycosis.Enhancing molecular approaches for diagnosis of fungal infections.Histopathological evidence of invasive gastric mucormycosis after transarterial chemoembolization and liver transplantation.Pathogenesis and host defence against Mucorales: the role of cytokines and interaction with antifungal drugs.Gastrointestinal mucormycosis in immunocompromised hosts.Hyperglycemia as a possible risk factor for mold infections-the potential preventative role of intensified glucose control in allogeneic hematopoietic stem cell transplantation.Apophysomyces variabilis: draft genome sequence and comparison of predictive virulence determinants with other medically important Mucorales.Rare fungal illness follows tornado.Tumor shape pulmonary mucormycosis associated with sinonasal aspergillosis in a diabetic patient.
P2860
Q28656453-237885CD-472B-4F9E-9B90-247116C449B4Q34315804-53719D79-2C18-42FC-9904-7A5FA5B2D14CQ34572967-B83F172B-6DEA-43DB-9467-1CD3F609BEDAQ34596443-C5F550C4-7805-4B56-BCAD-7D9982D749BDQ34733848-D9CAF97A-F809-4D7B-AB03-FA0FC3A7067CQ35757575-804542A3-1B3A-40B6-814E-570A42CBC08BQ36364013-4BD660EB-B177-4CE5-B200-7E5BFE66F7E9Q36584655-B74B3A8A-AAED-4A55-8946-AB2060CBFB2DQ37613070-451156BA-E7F1-4D04-B1C5-950DA79BD4C9Q38135904-9A5F8561-096D-477C-86B8-B778861405B4Q38165198-E7534C97-CFC8-4CA8-9B6A-7C585E17810AQ38193332-52E2ED0E-633A-407A-9A37-A7CF77E4962FQ38245046-1F61BEEA-123E-4831-A375-82BF8A94391AQ38604684-0CAB9546-225E-4695-A8B6-D928EF4F1D6DQ39035934-52007145-4013-4307-B51A-AEA5DB6529B4Q41704770-D1F45B36-98CC-4EF9-B571-25C6C6742900Q43182462-6E75A201-BFF0-4770-B16F-65E674A4B834Q46362200-2C3F1E93-93F6-46A7-B4E4-CE059FDEE9CF
P2860
How does antifungal pharmacology differ for mucormycosis versus aspergillosis?
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
How does antifungal pharmacology differ for mucormycosis versus aspergillosis?
@en
How does antifungal pharmacology differ for mucormycosis versus aspergillosis?
@nl
type
label
How does antifungal pharmacology differ for mucormycosis versus aspergillosis?
@en
How does antifungal pharmacology differ for mucormycosis versus aspergillosis?
@nl
prefLabel
How does antifungal pharmacology differ for mucormycosis versus aspergillosis?
@en
How does antifungal pharmacology differ for mucormycosis versus aspergillosis?
@nl
P2093
P50
P356
P1476
How does antifungal pharmacology differ for mucormycosis versus aspergillosis?
@en
P2093
Brad Spellberg
Dimitrios P Kontoyiannis
Thomas J Walsh
P304
P356
10.1093/CID/CIR884
P407
P478
54 Suppl 1
P577
2012-02-01T00:00:00Z